Non-Persistent Nano-Architectures Enhance Concurrent Chemoradiotherapy in an Immunocompetent Orthotopic Model of HPV+ Head/Neck Carcinoma.
Alessandra GonnelliMarine Gerbé de ThoréMaria Laura ErminiValentina FruscaAgata ZamborlinNicolas SignolleOlivia BawaCéline ClémensonLydia MezianiPaul BergeronIsmail El-AzrakPatrizia SarogniEnrico MugnaioliNoemi GianniniGiuliana DravaEric DeutschFabiola PaiarMichele MondiniValerio VolianiPublished in: Advanced materials (Deerfield Beach, Fla.) (2024)
Cisplatin chemoradiotherapy (CRT) is the established standard of care for managing HPV+ head/neck carcinoma. The typically young patients may suffer serious and long-time side effects caused by the treatment, such as dysphagia, and hearing loss. Thus, ensuring a satisfactory post-treatment quality of life is paramount. One potential replacing approach to the classical CRT involves the combination of standard-dose radiotherapy and radiosensitizers such as noble metal nanoparticles (NPs). However, several concerns about size, shape and biocompatibility limit the translation of metal nanomaterials to the clinical practice. Here, we demonstrate that a new model of non-persistent gold nano-architectures containing cisplatin (NAs-Cluster-CisPt) generates, in combination with radiotherapy, a significant in vivo tumor-reducing effect compared to the standard CRT, achieving a complete tumor clearance in 25% of the immunocompetent models that persisted for 60 days. These findings, together with the negligible amount of metals recognized in the excretory organs, highlight that the concurrent administration of NAs-Cluster-CisPt and radiotherapy has the potential to overcome some clinical limitations associated to NPs-based approaches while enhancing the treatment outcome respect to standard CRT. Overall, despite further mechanistic investigations being essential, our data support the exploiting of non-persistent metal nanomaterials mediated approaches for oral cancer management. This article is protected by copyright. All rights reserved.
Keyphrases
- locally advanced
- rectal cancer
- early stage
- radiation therapy
- squamous cell carcinoma
- cardiac resynchronization therapy
- end stage renal disease
- clinical practice
- radiation induced
- healthcare
- high grade
- human health
- heart failure
- hearing loss
- chronic kidney disease
- prognostic factors
- electronic health record
- atrial fibrillation
- climate change
- combination therapy